{"id":61596,"date":"2024-03-03T06:01:14","date_gmt":"2024-03-03T06:01:14","guid":{"rendered":"https:\/\/medsname.com\/bicalumutide\/"},"modified":"2026-04-30T10:23:34","modified_gmt":"2026-04-30T10:23:34","slug":"bicalumutide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nb\/product\/bicalumutide\/","title":{"rendered":"Bicalumutide"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">&#9889; Quick Answer &mdash; What is Bicalumutide?<\/h3>\n<p style=\"margin:0;\"><strong>Bicalumutide<\/strong> er en tablett fra Cipla som inneholder <strong>bicalutamide 50 mg<\/strong> \u2014 en ikke-steroid <strong>androgenreseptorantagonist (anti-androgen)<\/strong> brukt til <strong>avansert eller metastatisk prostatakreft<\/strong>. Standardrolle: brukes i kombinasjon med en <strong>LHRH-agonist<\/strong> (goserelin, leuprorelin) for kombinert androgenblokkade (CAB). Standarddose: <strong>50 mg once daily (with LHRH agonist) or 150 mg once daily (monotherapy)<\/strong>. Main side effects: gynaecomastia and breast tenderness (common), hot flushes, hepatotoxicity (mandatory LFT monitoring), reduced libido, rare interstitial pneumonitis. <strong>Obligatorisk: utgangsverdi + m\u00e5nedlige leverfunktionstester de f\u00f8rste 4 m\u00e5nedene, deretter periodisk.<\/strong><\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Hva du f\u00e5r med MedsBase:<\/strong> WHO-GMP-sertifisert produsent \u00b7 Diskret emballasje \u00b7 Verdensomspennende levering \u00b7 1 400+ verifiserte <a href=\"https:\/\/medsbase.com\/nb\/reviews\/\">kundeanmeldelser<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Hver ordre er dekket av v\u00e5r <a href=\"https:\/\/medsbase.com\/nb\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis pakken din ikke ankommer innen 20 virkedager, sender vi ny.<\/p>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:0 0 24px 0;border-radius:4px;font-size:14px;\"><strong>\u26a0 Spesialistveiledning kreves.<\/strong> Kreftmedisiner m\u00e5 foreskrives av en behandlende onkolog med bekreftet diagnose, utgangsstadium og en definert behandlingsplan. Start aldri, stopp aldri, endre dose eller bruk kreftmedisin utenfor en onkologiledet behandlingsplan. De fleste kreftmedisiner krever regelmessig blodpr\u00f8vekontroll (FBC, leverfunksjon, nyrefunksjon), er absolutt kontraindisert under svangerskap og har betydelige legemiddelinteraksjoner.<\/div>\n<h2 class=\"wp-block-heading\">What Is Bicalumutide?<\/h2>\n<p>Bicalumutide is an oral tablet from Cipla containing <strong>bicalutamide 50 mg<\/strong>. Bicalutamide is a non-steroidal anti-androgen that competitively blocks the androgen receptor in prostate cancer cells, inhibiting the proliferative effect of testosterone and dihydrotestosterone (DHT). It is used in <strong>avansert eller metastatisk prostatakreft<\/strong>, nesten alltid kombinert med en LHRH-agonist (goserelin, leuprorelin, triptorelin) for <strong>kombinert androgenblokkade (CAB)<\/strong>.<\/p>\n<h2 class=\"wp-block-heading\">How Does Bicalumutide Work?<\/h2>\n<p>Prostate cancer growth is driven by androgen-receptor signalling. Standard androgen deprivation therapy (ADT) suppresses ovarian androgen production through LHRH agonists. However, the adrenal glands continue to produce ~10% of total body androgens, and the residual signal is enough to drive disease progression in many patients. Bicalumutide blocks the androgen receptor itself, so the residual adrenal androgens cannot signal &mdash; producing more complete androgen blockade.<\/p>\n<ul>\n<li><strong>Kompetitiv androgenreseptorantagonist<\/strong> \u2014 binder AR og hindrer testosteron\/DHT i \u00e5 aktivere den.<\/li>\n<li><strong>Long half-life (~6 days)<\/strong> &mdash; once-daily oral dosing.<\/li>\n<li><strong>Brukes for \u00e5 forhindre \u201ctum\u00f8rflamme\u201d<\/strong> ved p\u00e5start av LHRH-agonistterapi \u2014 den f\u00f8rste LHRH-induserte testosteron\u00f8kningen kan midlertidig forverre sykdommen, og forbehandling med antiandrogen blokkerer dette.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Bruk og indikasjoner<\/h2>\n<ul>\n<li><strong>Kombinert androgenblokkade (CAB)<\/strong> ved avansert eller metastatisk prostatakreft (med LHRH-agonist)<\/li>\n<li><strong>Forebygging av tum\u00f8rflamme<\/strong> ved p\u00e5start av LHRH-agonist (2\u20134 uker forbehandling)<\/li>\n<li><strong>Monotherapy 150 mg\/day<\/strong> in locally advanced non-metastatic prostate cancer (alternative to LHRH agonist for patients prioritising sexual function preservation)<\/li>\n<li><strong>Etter biokjemisk tilbakefall<\/strong> som del av intermitterende eller kontinuerlig androgendepriveringsregimer<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Bicalumutide Dosage and How to Take<\/h2>\n<p>Standard dose: <strong>50 mg once daily (with LHRH agonist) or 150 mg once daily (monotherapy)<\/strong>.<\/p>\n<ol>\n<li><strong>En gang daglig p\u00e5 samme tid hver dag.<\/strong> Med eller uten mat.<\/li>\n<li><strong>Svelg hel med vann.<\/strong><\/li>\n<li><strong>Obligatorisk overv\u00e5king:<\/strong> basisverdier for leverfunksjonstester (AST, ALT) og PSA. Gjenta leverfunksjonstester <strong>m\u00e5nedlig de f\u00f8rste 4 m\u00e5nedene<\/strong>, deretter hver 3.\u20136. m\u00e5ned. PSA hver 3. m\u00e5ned. Stopp og unders\u00f8k hvis AST\/ALT &gt; 3\u00d7 \u00f8vre normalgrense.<\/li>\n<li><strong>Forebygging av tumorfl\u00f8rr f\u00f8r LHRH-agonist:<\/strong> start Bicalumutide 2&ndash;4 weeks before LHRH agonist initiation, continue for at least 1 month after.<\/li>\n<li><strong>Ikke stopp uten onkologs instruks.<\/strong><\/li>\n<\/ol>\n<h2 class=\"wp-block-heading\">Side Effects of Bicalumutide<\/h2>\n<p><strong>Vanlig:<\/strong><\/p>\n<ul>\n<li>Gyn\u00e6komasti og bryst\u00f8mhet (40\u201370% ved monoterapi; mindre ved CAB)<\/li>\n<li>Hettetokter<\/li>\n<li>Redusert libido og erektil dysfunksjon<\/li>\n<li>Trethet, svakhet<\/li>\n<li>Diar\u00e9 (spesielt ved flutamid)<\/li>\n<li>Mild mageubehag<\/li>\n<\/ul>\n<p><strong>Viktig \u2014 obligatorisk overv\u00e5king:<\/strong><\/p>\n<ul>\n<li><strong>Hepatotoksistet<\/strong> \u2014 kan v\u00e6re alvorlig og uforutsigbar. Stopp umiddelbart ved gulsott, m\u00f8rk urin, alvorlig tretthet eller AST\/ALT &gt; 3\u00d7 ULN. De fleste tilfeller oppst\u00e5r innen de f\u00f8rste 4 m\u00e5nedene.<\/li>\n<li>Rare interstitial pneumonitis &mdash; new-onset cough, dyspnoea<\/li>\n<\/ul>\n<p><strong>Sjeldne:<\/strong> hemolytisk anemi, fotosensitivitet, alvorlige hudreaksjoner.<\/p>\n<h2 class=\"wp-block-heading\">Advarsler og forholdsregler<\/h2>\n<ul>\n<li><strong>Graviditet og amming:<\/strong> ikke aktuelt (kun for menn), men antiandrogener er fostertoksiske hvis de tas ved feil under graviditet.<\/li>\n<li><strong>Levefunksjon:<\/strong> obligatoriske m\u00e5nedlige leverfunksjonstester de f\u00f8rste 4 m\u00e5nedene. Stopp ved AST\/ALT &gt; 3\u00d7 ULN.<\/li>\n<li><strong>Diabetes:<\/strong> kan forverre glykemisk kontroll.<\/li>\n<li><strong>Kardiovaskul\u00e6re:<\/strong> ADT generelt er assosiert med \u00f8kte kardiovaskul\u00e6re hendelser. Optimaliser modifiserbare risikofaktorer.<\/li>\n<li><strong>Forebygging av gynekomasti:<\/strong> lavdose tamoksifen 10\u201320 mg\/dag eller profylaktisk bryststr\u00e5lebehandling reduserer forekomst (spesialist).<\/li>\n<li><strong>Kj\u00f8ring:<\/strong> forsiktighet \u2014 tretthet og svimmelhet kan p\u00e5virke kj\u00f8reevnen.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Legemiddelinteraksjoner<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:12px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;\">Kombiner med<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;\">Effekt<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;\">Hva du b\u00f8r gj\u00f8re<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Warfarin og andre kumarinantikoagulantia<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Betydelig \u00f8kning i INR \u2014 bl\u00f8dningsrisiko<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Kontroller INR ukentlig i starten. Reduser warfarindosen med 30\u201350%.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">CYP3A4 inhibitors (minor effect)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Raise bicalutamide levels<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Overv\u00e5k for hepatotoksisk effekt.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">LHRH-agonister (goserelin, leuprorelin)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Standard kombinasjon \u2013 kombinert androgenblokkade<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Standard CAB-regime.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Alkohol<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Additiv hepatotoksisk effekt<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Begrens alkoholinntak under behandling.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 class=\"wp-block-heading\">Oppbevaring<\/h2>\n<ul>\n<li>Oppbevares ved romtemperatur, 15\u201325\u00b0C, i originalblister.<\/li>\n<li>Hold utilgjengelig for barn, kvinner og kj\u00e6ledyr \u2013 antiandrogener er fostertoksiske.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Relaterte alternativer p\u00e5 MedsBase<\/h2>\n<p>Andre onkologimedikamenter vi f\u00f8rer sammen med dette produktet:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/nb\/bdenza\/\"><strong>Bdenza (enzalutamide 40 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/cytomid\/\"><strong>Cytomid (flutamide 250 mg)<\/strong><\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/medsbase.com\/nb\/anti-cancer-medication\/\">Se alle kreftmedikamenter \u2192<\/a><\/p>\n<h2 id=\"faqs\">Vanlige sp\u00f8rsm\u00e5l<\/h2>\n<h3 class=\"wp-block-heading\">Why is Bicalumutide usually combined with an LHRH agonist?<\/h3>\n<p>LHRH agonists (goserelin, leuprorelin) suppress testicular androgen production, but the adrenal glands continue producing ~10% of body androgens that can drive prostate cancer growth. Bicalumutide blocks the androgen receptor itself, so adrenal androgens cannot signal. The combination is called <strong>kombinert androgenblokkade (CAB)<\/strong> og gir en dypere androgenhemming enn LHRH-agonist alene ved avansert sykdom.<\/p>\n<h3 class=\"wp-block-heading\">What is &ldquo;tumour flare&rdquo; and why does Bicalumutide prevent it?<\/h3>\n<p>When LHRH agonist therapy starts, the pituitary is initially stimulated and testosterone surges for 1&ndash;2 weeks before downregulation kicks in. In patients with significant disease burden (bone metastases, urinary obstruction, spinal cord compression risk), this transient testosterone surge can worsen symptoms acutely. Starting Bicalumutide 2&ndash;4 weeks before the LHRH agonist blocks the receptor and prevents the flare.<\/p>\n<h3 class=\"wp-block-heading\">Hvordan h\u00e5ndteres gynekomasti?<\/h3>\n<p>Bryst\u00f8mhet og gynekomasti p\u00e5virker 40\u201370% av pasienter p\u00e5 bikalutamid monoterapi ved h\u00f8yere doser. Forebyggende tiltak inkluderer: <strong>lavdose tamoksifen 10\u201320 mg\/dag<\/strong> (mest dokumentert effekt) eller <strong>profylaktisk bryststr\u00e5lebehandling<\/strong> som en enkelt dose p\u00e5 8\u201312 Gy f\u00f8r start av anti-androgenbehandling. Diskuter med onkolog f\u00f8r start hvis kosmetiske bekymringer er betydelige.<\/p>\n<h3 class=\"wp-block-heading\">Hvilke blodpr\u00f8ver trenger jeg?<\/h3>\n<p><strong>Obligatorisk:<\/strong> baseline leverfunksjonstester (AST, ALT) og PSA. Deretter leverfunksjonstester <strong>m\u00e5nedlig de f\u00f8rste 4 m\u00e5nedene<\/strong>, then every 3&ndash;6 months. PSA every 3 months. Stop Bicalumutide immediately and contact your oncologist if AST\/ALT &gt; 3&times; ULN, or for any jaundice, dark urine or severe fatigue.<\/p>\n<h3 class=\"wp-block-heading\">Can I drink alcohol on Bicalumutide?<\/h3>\n<p>Limit alcohol &mdash; both alcohol and bicalutamide are hepatotoxic and the combination amplifies the risk of severe drug-induced liver injury. Occasional small amounts are usually tolerable; heavy or daily drinking should be avoided throughout treatment.<\/p>\n<h3 class=\"wp-block-heading\">Bicalumutide vs flutamide vs enzalutamide &mdash; what is the difference?<\/h3>\n<p>All three are oral anti-androgens for prostate cancer. <strong>Bicalutamide:<\/strong> once-daily, well-tolerated, standard first-generation choice. <strong>Flutamide:<\/strong> three-times-daily, more diarrhoea and hepatotoxicity risk &mdash; largely replaced by bicalutamide. <strong>Enzalutamide:<\/strong> second-generation, more potent, used for castration-resistant disease (after CAB has failed) &mdash; see <a href=\"https:\/\/medsbase.com\/nb\/bdenza\/\">Bdenza<\/a>.<\/p>\n<h3 class=\"wp-block-heading\">Will Bicalumutide affect my heart?<\/h3>\n<p>Antiandrogen monoterapi har minimal direkte kardiovaskul\u00e6r effekt, men bredere androgendepriverende terapi (LHRH-agonist + antiandrogen) er assosiert med \u00f8kt risiko for kardiovaskul\u00e6re hendelser inkludert hjerteinfarkt og slag. Optimaliser kardiovaskul\u00e6re risikofaktorer: blodtrykkskontroll, statin ved hyperlipidemi, r\u00f8ykeslutt, trening og vektkontroll.<\/p>\n<h3 class=\"wp-block-heading\">Can I stop Bicalumutide if PSA stays low?<\/h3>\n<p>Diskuter med onkologen din. I noen intermittierende CAB-protokoller holdes CAB tilbake n\u00e5r PSA er undertrykt under terskel og gjenopptas n\u00e5r PSA stiger \u2014 dette kan redusere bivirkninger uten \u00e5 p\u00e5virke overlevelse. Stopp aldri p\u00e5 egen h\u00e5nd \u2014 PSA-overv\u00e5kning og tidspunkt for gjenoppstart er avgj\u00f8rende.<\/p>\n<div style=\"background:#f4f8fb;border:1px solid #d6e4ec;padding:12px 18px;margin:14px 0;border-radius:4px;font-size:14px;color:#3a5160;text-align:center;\">\n<strong>\ud83d\udd12 Kryptert utsjekking<\/strong> \u00b7 <strong>\ud83d\udcb3 Verifisert betalingsbehandler<\/strong> \u00b7 <strong>\ud83d\ude9a Verdensomspennende frakt<\/strong> \u00b7 <strong>\u2b50 4,9\/5 fra 1 400+ kunder<\/strong>\n<\/div>\n<p><!-- medsbase-why-order --><\/p>\n<h3>Hvorfor bestille fra MedsBase<\/h3>\n<p>Hver batch er hentet fra en <strong>WHO-GMP-sertifisert produsent<\/strong>. Bestillinger sendes i enkel, umerkembar emballasje fra v\u00e5re oppfyllelsespartnere og er dekket av v\u00e5r <a href=\"\/nb\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>: hvis en pakke ikke ankommer innen 20 virkedager sender vi en gratis etterforsendelse, uten sp\u00f8rsm\u00e5l.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Relaterte alternativer<\/h3>\n<p>Andre produkter innen <strong>Kroniske tilstander<\/strong> som kunder ogs\u00e5 ser p\u00e5:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/nb\/riborea\/\">Riborea<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/bacloheal\/\">Bacloheal<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/amlode\/\">Amlode<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/nicerbium\/\">Nicerbium<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nb\/lipril-h\/\">Lipril-H<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Behandler prostatakreft<br \/>\n\u2705 Blocks male hormones<br \/>\n\u2705 Reduserer svulstvekst<br \/>\n\u2705 Forbedrer overlevelsessatser<br \/>\n\u2705 Reduces cancer symptoms<\/p>\n<p>Bicalumutide contains Bicalutamide.<\/p>","protected":false},"featured_media":61597,"comment_status":"closed","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3595,3614,3141,3223,3342],"product_tag":[5066,5067],"class_list":{"0":"post-61596","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_cat-bladder-prostate","8":"product_cat-category-overview","9":"product_cat-chronic-conditions","10":"product_cat-general-health","11":"product_tag-bicalumutide","12":"product_tag-bicalutamide","14":"first","15":"instock","16":"shipping-taxable","17":"purchasable","18":"product-type-variable","19":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product\/61596","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/comments?post=61596"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/media\/61597"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/media?parent=61596"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product_brand?post=61596"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product_cat?post=61596"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/nb\/wp-json\/wp\/v2\/product_tag?post=61596"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}